ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 102 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.45 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,708,597 | -44.3% | 510,094 | +0.0% | 0.00% | -50.0% |
| Q2 2023 | $4,859,151 | -12.9% | 509,879 | +0.4% | 0.00% | 0.0% |
| Q1 2023 | $5,577,846 | -35.1% | 508,019 | -12.5% | 0.00% | -42.9% |
| Q4 2022 | $8,597,157 | -22.8% | 580,889 | -0.4% | 0.01% | -30.0% |
| Q3 2022 | $11,140,000 | -7.4% | 582,936 | +3.2% | 0.01% | 0.0% |
| Q2 2022 | $12,032,000 | +19.1% | 564,644 | +7.6% | 0.01% | +42.9% |
| Q1 2022 | $10,103,000 | +0.0% | 524,559 | +7.7% | 0.01% | +16.7% |
| Q4 2021 | $10,102,000 | +12.4% | 487,071 | +29.5% | 0.01% | 0.0% |
| Q3 2021 | $8,985,000 | -12.6% | 376,074 | -0.1% | 0.01% | -14.3% |
| Q2 2021 | $10,278,000 | -5.5% | 376,620 | +0.2% | 0.01% | -12.5% |
| Q1 2021 | $10,872,000 | +34.1% | 375,796 | +30.3% | 0.01% | +33.3% |
| Q4 2020 | $8,110,000 | – | 288,300 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $314,175,000 | 35.62% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $118,583,000 | 20.06% |
| Omega Fund Management, LLC | 844,680 | $25,171,000 | 10.42% |
| Vivo Capital, LLC | 1,686,527 | $50,259,000 | 4.55% |
| Orbimed Advisors | 4,673,850 | $139,281,000 | 2.34% |
| RA Capital Management | 1,165,184 | $34,722,000 | 1.10% |
| Polar Capital LLP | 375,000 | $11,175,000 | 0.12% |
| CAAS CAPITAL MANAGEMENT LP | 22,413 | $668,000 | 0.07% |
| FMR LLC | 5,713,343 | $170,258,000 | 0.02% |
| Laurion Capital Management LP | 50,000 | $1,490,000 | 0.02% |